GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.49 (+0.44%)

Growth Price

Overvalued by 13.07%

Stability Price

Overvalued by 65.53%

Company Metrics

  • 12.74 P/E
  • 5.95 P/S
  • 9.56 P/B
  • 8.77 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 1.72 / 1.70 % Dividend
  • 10.77M Avg. Vol.
  • 164.17B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


SWOT Analysis of Gilead Sciences Inc. Stock
Motley Fool - May 20, 2015
Over the short run, that question is next to impossible to answer. Over the long run, though, investors can project how well Gilead stock (or any other stock, for that matter) should perform with at least a reasonable level of confidence. The key is to ...
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Update - Bidness ETC
Gilead Sciences: Finally Gaining Momentum (GILD) - Seeking Alpha
Is AbbVie Inc Getting Ahead Of Gilead Sciences, Inc. And Johnson & Johnson?
Bidness ETC - May 18, 2015
AbbVie Inc (NYSE:ABBV) might just be getting ahead of its competitors in HCV and Immunology market, including Gilead Sciences, Inc. (NASDAQ:GILD), and Johnson & Johnson (NYSE:JNJ). AbbVie's HCV drug Viekira Pak has witnessed better prescription ...
Why Are Prescription Drugs So Expensive? Big Pharma Points To The Cost Of ... - International Business Times
Gilead Sciences, Inc. (GILD) May Have Found A Cure For HIV
Smarter Analyst - May 19, 2015
When you think of Gilead Sciences, what's the first thing that comes to mind. If you're like most investors, the answer is the hepatitis C virus.
Here's How Potential Competition With Gilead Sciences Affected Achillion ... - Bidness ETC
Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J - Barron's (blog)
Biogen Inc, Gilead Sciences, Inc., Orexigen Therapeutics, Inc.: Best Biotech ...
ETF Daily News - May 11, 2015
Gilead Sciences Inc. (Nasdaq: GILD) is down 0.6% since early February. Gilead's biggest revenue generator is Sovaldi, a Hepatitis C drug that costs $1,000 per pill.
Gilead Sciences Is Poised To Break Out - Seeking Alpha
Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs - Wall Street Journal (blog)
The Most Loved Biotechs of Big Hedge Funds
24/7 Wall St. - 19 hours ago
Gilead Sciences Inc. (NASDAQ: GILD) is no shocker at all to see on the list. After all, it has grown and grown, and it has a market cap of $164 billion.
Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?
Motley Fool - May 5, 2015
That's why I'm starting to suspect that Gilead might bolster its oncology pipeline via an acquisition soon. While there's a lot of speculation that the biotech will pursue companies developing either hep C or HIV treatments, I think investors need to ...
Gilead Sciences, Inc. (GILD) Tops the Barron's 500 List - Bidness ETC
Gilead Sciences: Strong Growth, Poor Stock Performance (GILD) - Seeking Alpha
Gilead Sciences's "Buy" Rating Reaffirmed at Deutsche Bank (GILD)
Dakota Financial News - 9 hours ago
Gilead Sciences, Inc. logo Deutsche Bank reaffirmed their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Saturday.
Gilead Sciences Given Overweight Rating at Morgan Stanley (GILD) - WKRB News
Insider Selling News: Gilead Sciences, Inc. (GILD), Walt Disney Co (DIS ...
Smarter Analyst - May 20, 2015
Paul Rutherford Carter, Executive Vice President of Commercial Operations, unloaded 6,000 Gilead Sciences shares, valued at $660,000, in a transaction dated May 15.
Sizzling News Alert: Gilead Sciences, Inc. (NASDAQ:GILD), Dollar General Corp ...
wsnewspublishers - May 20, 2015
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific.
Updating My Price Target On Gilead Sciences (GILD)
Seeking Alpha - May 1, 2015
Gilead Sciences (NASDAQ:GILD) continues to generate significant investor interest due to its eye popping revenue growth. The vast majority of the growth in revenue and earnings stems from their Hepatitis C franchise (HCV) which continues to dominate ...
Gilead Sciences, Inc. And Visa Inc Beat Earnings Estimates - Smarter Analyst
Gilead Sciences: Blowout Earnings Won't Be 'Changing Too Many Opnions' - Barron's (blog)